Abbott Laboratories $ABT Shares Purchased by Ameriprise Financial Inc.

Ameriprise Financial Inc. increased its holdings in Abbott Laboratories (NYSE:ABT) by 3.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 13,500,829 shares of the healthcare product maker’s stock after purchasing an additional 499,351 shares during the quarter. Ameriprise Financial Inc. owned 0.78% of Abbott Laboratories worth $1,804,050,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Norges Bank acquired a new position in shares of Abbott Laboratories during the 2nd quarter worth approximately $3,026,180,000. Laurel Wealth Advisors LLC grew its stake in Abbott Laboratories by 13,347.0% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 6,056,934 shares of the healthcare product maker’s stock valued at $823,804,000 after acquiring an additional 6,011,891 shares during the period. Invesco Ltd. increased its holdings in Abbott Laboratories by 51.0% in the 3rd quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock worth $1,868,718,000 after acquiring an additional 4,713,135 shares in the last quarter. Vanguard Group Inc. raised its position in Abbott Laboratories by 1.8% during the second quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock worth $23,502,644,000 after acquiring an additional 2,977,715 shares during the period. Finally, First Trust Advisors LP lifted its holdings in Abbott Laboratories by 180.7% during the second quarter. First Trust Advisors LP now owns 3,063,443 shares of the healthcare product maker’s stock valued at $416,659,000 after purchasing an additional 1,972,097 shares in the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Abbott Laboratories news, EVP Mary K. Moreland sold 613 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $70,850.54. Following the transaction, the executive vice president owned 104,291 shares of the company’s stock, valued at $12,053,953.78. This represents a 0.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, VP John A. Jr. Mccoy sold 585 shares of Abbott Laboratories stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $67,614.30. Following the sale, the vice president owned 24,628 shares of the company’s stock, valued at approximately $2,846,504.24. This represents a 2.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is currently owned by company insiders.

Abbott Laboratories Trading Down 0.1%

Shares of ABT stock opened at $107.99 on Friday. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. Abbott Laboratories has a twelve month low of $105.27 and a twelve month high of $139.06. The company’s 50-day moving average price is $114.58 and its 200-day moving average price is $123.86. The stock has a market cap of $187.66 billion, a price-to-earnings ratio of 29.03, a PEG ratio of 1.72 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The company had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. During the same period in the previous year, the firm earned $1.34 earnings per share. Abbott Laboratories’s quarterly revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, equities analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 annualized dividend and a yield of 2.3%. Abbott Laboratories’s dividend payout ratio (DPR) is 67.74%.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. Leerink Partners cut their target price on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a research note on Friday, January 30th. Weiss Ratings cut Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 26th. Sanford C. Bernstein dropped their price target on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. The Goldman Sachs Group lowered their target price on shares of Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a research note on Friday, January 23rd. Finally, Citigroup reduced their target price on shares of Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating for the company in a research report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $136.16.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.